POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS

医学 轴性脊柱炎 葡萄膜炎 内科学 强直性脊柱炎 眼科 骶髂关节炎
作者
Martín Rudwaleit,Matthew Arthur Brown,Floris A van Gaalen,Nigil Haroon,Lianne S. Gensler,Carmen Fleurinck,Alexander Marten,Ute Massow,Natasha de Peyrecave,Thomas Vaux,Katy White,Atul A. Deodhar,Irene E. van der Horst-Bruinsma
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: 614.2-615 被引量:2
标识
DOI:10.1136/annrheumdis-2023-eular.1702
摘要

Background Acute anterior uveitis (‘uveitis’), or ‘iritis’, is a common extra musculoskeletal manifestation among patients (pts) with axial spondyloarthritis (axSpA). The prevalence of uveitis varies with HLA-B27 positivity, axSpA subtype and disease duration, reaching >50% in radiographic (r)-axSpA (i.e., ankylosing spondylitis) [1] pts with >40 years symptom duration [2]. Interleukin (IL)-17 has been implicated in the pathogenesis of uveitis; however, inhibition of IL-17A alone may not be optimal for the management of uveitis [3]. Here, we report the incidence of uveitis following inhibition of IL-17A in addition to IL‑17F with bimekizumab (BKZ). Objectives To compare incidence rates of uveitis in pts with axSpA treated with placebo (PBO) or BKZ 160 mg every four weeks (wks; Q4W) to Wk 16 of the phase (ph)3 trials BE MOBILE 1 and 2. To evaluate incidence rates of uveitis in pts with axSpA treated with BKZ 160 mg Q4W, using pooled ph2b/3 data. Methods The ph3 studies BE MOBILE 1 (NCT03928704; non-r-axSpA) and 2 (NCT03928743; r‑axSpA) comprised a 16-wk double-blind treatment period (DBTP; subcutaneous BKZ 160 mg Q4W or PBO) followed by a 36‑wk maintenance period (all pts received BKZ 160 mg Q4W) [5]. Upon entry to the ongoing BE MOVING open-label extension (OLE; [NCT04436640; cut-off 4 Jul 2022]) at Wk 52, all pts remained on BKZ 160 mg Q4W. The ph2b study BE AGILE (NCT02963506; r-axSpA) comprised a 12‑wk double-blind, dose-ranging period followed by a 36-wk randomised period (BKZ 160 or 320 mg Q4W) [4]. Upon entry to the ongoing BE AGILE OLE (NCT03355573; cut-off 4 Jul 2022) at Wk 48, all pts received BKZ 160 mg Q4W. Data were pooled for all pts treated with BKZ 160 mg Q4W in the ph2b/3 trials listed above. Data were pooled separately for pts randomised to BKZ or PBO in the DBTP of BE MOBILE 1 and 2. Uveitis treatment-emergent adverse events (TEAEs) were identified using the preferred terms “autoimmune uveitis”, “iridocyclitis”, “iritis”, and “uveitis”, and were reported as both incidence and exposure adjusted incidence rates (EAIRs) per 100 pt years (PY) for all pts who received ≥1 BKZ dose. Results Baseline characteristics were reflective of a pt population with moderate-to-severe axSpA (Table 1). In the DBTP of BE MOBILE 1 and 2, uveitis TEAEs occurred in 11/237 (4.6%; EAIR/100 PY [95% CI]: 15.4 [7.7, 27.5]) and 2/349 (0.6%; 1.8 [0.2, 6.7]) of pts randomised to PBO and BKZ (% difference [95% CI]: 4.07 [1.71, 7.60]), respectively (Figure 1). In the 45 PBO-randomised (19.0%) and 52 BKZ-randomised (14.9%) pts with history of uveitis, uveitis TEAEs occurred in 20.0% (EAIR/100 PY [95% CI]: 70.4 [32.2, 133.7]) and 1.9% (6.2 [0.2, 34.8]) of pts, respectively. In the pooled ph2b/3 trial data, total BKZ exposure was 2,034.4 PY (N=848), 130 (15.3%) pts had history of uveitis. Uveitis TEAEs occurred in 25 (2.9%; EAIR/100 PY [95% CI]: 1.2 [0.8, 1.8]) and 14 (10.8%; 4.6 [2.5, 7.7]) pts overall and with history of uveitis, respectively (Figure 1). All uveitis TEAEs were mild/moderate, one event led to discontinuation. Conclusion The incidence rate of uveitis TEAEs was lower to Wk 16 in axSpA pts randomised to BKZ 160 mg Q4W vs PBO. In the largest pool of ph2b/3 data available at the time of this report, the incidence rate of uveitis with BKZ 160 mg Q4W remained low at 1.2/100 PY. Reference [1]Boel A. Ann Rheum Dis 2019;78:1545–9; 2. Robinson PC. Arthritis Rheumatol. 2015;67(1):140–51; 3. Dick AD. J. Opthalmol 2013;120(4):777–87; 4. van der Heijde D. Ann Rheum Dis 2020;79:595–604; 5. Baraliakos X. Arthritis Rheumatol 2022;74 (suppl 9). Acknowledgements This study was funded by UCB Pharma. Medical writing support was provided by Costello Medical, funded by UCB Pharma. Disclosure of Interests Martin Rudwaleit Speakers bureau: AbbVie, Boehringer Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Novartis and UCB Pharma, Matthew Brown Speakers bureau: Novartis., Consultant of: Clementia, Grey Wolf Therapeutics, Incyte, Ipsen, Pfizer, Regeneron and Xinthera, Grant/research support from: UCB Pharma, Floris A. van Gaalen Consultant of: Fees from Novartis; personal fees from AbbVie, BMS, Eli Lilly and MSD, Grant/research support from: Jacobus Stichting, Novartis, Stichting ASAS, Stichting Vrienden van Sole Mio and UCB Pharma, Nigil Haroon Consultant of: AbbVie, Eli Lilly, Janssen, Novartis and UCB Pharma, Lianne S. Gensler Consultant of: AbbVie, Acelyrin, Eli Lilly, Fresenius Kabi, Gilead, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma, Grant/research support from: Novartis and UCB Pharma paid to institution, Carmen Fleurinck Employee of: UCB Pharma, Alexander Marten Employee of: UCB Pharma, Ute Massow Employee of: UCB Pharma, Natasha de Peyrecave Employee of: UCB Pharma, Thomas Vaux Employee of: UCB Pharma, Katy White Shareholder of: UCB Pharma, Employee of: UCB Pharma, Atul Deodhar Speakers bureau: Janssen, Novartis and Pfizer, Consultant of: AbbVie, Amgen, Aurinia, BMS, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma, Irene van der Horst-Bruinsma Speakers bureau: AbbVie, BMS, MSD and Pfizer, Consultant of: Abbvie, Lilly, MSD, Novartis and UCB Pharma, Grant/research support from: Unrestricted grants received for investigator-initiated studies from AbbVie, MSD, Pfizer and UCB Pharma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方的应助被675675采纳,获得10
刚刚
幸福台灯完成签到,获得积分10
刚刚
Captainhana完成签到,获得积分10
2秒前
3秒前
嘤嘤嘤发布了新的文献求助10
4秒前
三千白发生完成签到,获得积分10
4秒前
纳古菌完成签到,获得积分10
5秒前
SG完成签到,获得积分10
5秒前
听话的无极完成签到,获得积分10
5秒前
5秒前
123456完成签到,获得积分10
6秒前
努力小人完成签到,获得积分10
6秒前
7秒前
liang完成签到,获得积分10
7秒前
7秒前
青葙完成签到,获得积分10
8秒前
123456发布了新的文献求助10
9秒前
11NING发布了新的文献求助10
10秒前
Ysk完成签到,获得积分10
10秒前
12秒前
675675发布了新的文献求助10
14秒前
汉堡包的应助被小艾同学采纳,获得10
14秒前
15秒前
18秒前
11NING完成签到,获得积分10
18秒前
18秒前
SCI完成签到,获得积分10
19秒前
Koi发布了新的文献求助10
19秒前
禹hs完成签到,获得积分10
22秒前
吱ing完成签到 ,获得积分10
23秒前
ding的应助被bbb采纳,获得10
23秒前
SCI发布了新的文献求助10
23秒前
ZeSheng完成签到,获得积分10
24秒前
25秒前
25秒前
25秒前
眠龙完成签到 ,获得积分10
26秒前
猪猪侠完成签到,获得积分10
27秒前
27秒前
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568